Heparin-Induced Thrombocytopenia Diagnosis and Management

Introduction to Heparin-Induced Thrombocytopenia

The American Society of Hematology recommends that heparin-induced thrombocytopenia (HIT) be suspected in patients who develop thrombocytopenia after heparin therapy, with a decrease in platelet count of 30-70 G/L or a fall of >50% from baseline 4
The European Hematology Association suggests that HIT typically occurs between 5-10 days after the start of heparin treatment, but can appear earlier in patients who have been exposed to heparin in the past 3 months 4, 5
The International Society on Thrombosis and Haemostasis states that HIT is strongly associated with thrombotic complications, rather than bleeding manifestations 5

The American College of Chest Physicians recommends that the risk of HIT be assessed based on the type of heparin used and the clinical context, with a low risk (<0.1%) associated with low molecular weight heparin (LMWH) in non-oncologic medical contexts 1, 2, 3
The British Committee for Standards in Haematology suggests that the risk of HIT is higher (0.1-1%) in patients with cancer, severe trauma, or those undergoing surgery, including cardiac surgery 6
The American Heart Association states that the risk of HIT is high (>1%) with unfractionated heparin (UFH) in surgical contexts, including cardiac surgery and renal replacement therapy 1, 2, 3

The International Society on Thrombosis and Haemostasis recommends that the 4T score be used to evaluate the likelihood of HIT, based on the degree of thrombocytopenia, timing of thrombocytopenia, presence of thrombosis, and absence of other causes of thrombocytopenia 4, 5
The American Society of Hematology suggests that a 4T score of ≤3 points indicates a low probability of HIT, while a score of 4-5 points indicates an intermediate probability, and a score of ≥6 points indicates a high probability 4
The European Hematology Association recommends that laboratory tests, such as the detection of anti-PF4/heparin antibodies, be used to confirm the diagnosis of HIT 1, 3

The American College of Chest Physicians recommends that heparin therapy be discontinued immediately in patients suspected of having HIT, and that alternative anticoagulation be initiated 1, 3
The British Committee for Standards in Haematology suggests that the management of HIT include the use of non-heparin anticoagulants, such as fondaparinux or argatroban, and the avoidance of platelet transfusions unless there is a high risk of bleeding 1, 3
The International Society on Thrombosis and Haemostasis states that the diagnosis and management of HIT require a multidisciplinary approach, involving hematologists, cardiologists, and other specialists 1, 3